Literature DB >> 21971592

Chemotherapy: Hodgkin lymphoma--absence of evidence not evidence of absence!

Peter Borchmann, Andreas Engert, Volker Diehl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21971592     DOI： 10.1038/nrclinonc.2011.149

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.

Authors:  A Santoro; G Bonadonna; P Valagussa; R Zucali; S Viviani; F Villani; A M Pagnoni; V Bonfante; R Musumeci; F Crippa
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

2.  The past: what we have learned in the last decade.

Authors:  Peter Borchmann; Andreas Engert
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

3.  Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

Authors:  David B Duggan; Gina R Petroni; Jeffrey L Johnson; John H Glick; Richard I Fisher; Joseph M Connors; George P Canellos; Bruce A Peterson
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

4.  ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Authors:  Simonetta Viviani; Pier Luigi Zinzani; Alessandro Rambaldi; Ercole Brusamolino; Alessandro Levis; Valeria Bonfante; Umberto Vitolo; Alessandro Pulsoni; Anna Marina Liberati; Giorgina Specchia; Pinuccia Valagussa; Andrea Rossi; Francesco Zaja; Enrico M Pogliani; Patrizia Pregno; Manuel Gotti; Andrea Gallamini; Delia Rota Scalabrini; Gianni Bonadonna; Alessandro M Gianni
Journal:  N Engl J Med       Date:  2011-07-21       Impact factor: 91.245

5.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD.

Authors:  G P Canellos; J R Anderson; K J Propert; N Nissen; M R Cooper; E S Henderson; M R Green; A Gottlieb; B A Peterson
Journal:  N Engl J Med       Date:  1992-11-19       Impact factor: 91.245

6.  Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Authors:  Andreas Engert; Volker Diehl; Jeremy Franklin; Andreas Lohri; Bernd Dörken; Wolf-Dieter Ludwig; Peter Koch; Mathias Hänel; Michael Pfreundschuh; Martin Wilhelm; Lorenz Trümper; Walter-Erich Aulitzky; Martin Bentz; Mathias Rummel; Orhan Sezer; Hans-Konrad Müller-Hermelink; Dirk Hasenclever; Markus Löffler
Journal:  J Clin Oncol       Date:  2009-08-24       Impact factor: 44.544

7.  ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.

Authors:  Massimo Federico; Stefano Luminari; Emilio Iannitto; Giuseppe Polimeno; Luigi Marcheselli; Antonella Montanini; Antonio La Sala; Francesco Merli; Caterina Stelitano; Samantha Pozzi; Renato Scalone; Nicola Di Renzo; Pellegrino Musto; Luca Baldini; Giulia Cervetti; Francesco Angrilli; Patrizio Mazza; Maura Brugiatelli; Paolo G Gobbi
Journal:  J Clin Oncol       Date:  2009-01-05       Impact factor: 44.544

8.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.

Authors:  Volker Diehl; Jeremy Franklin; Michael Pfreundschuh; Bernd Lathan; Ursula Paulus; Dirk Hasenclever; Hans Tesch; Richard Herrmann; Bernd Dörken; Hans-Konrad Müller-Hermelink; Eckhardt Dühmke; Markus Loeffler
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245
  8 in total
  2 in total

1.  Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.

Authors:  David W Scott; Fong Chun Chan; Fangxin Hong; Sanja Rogic; King L Tan; Barbara Meissner; Susana Ben-Neriah; Merrill Boyle; Robert Kridel; Adele Telenius; Bruce W Woolcock; Pedro Farinha; Richard I Fisher; Lisa M Rimsza; Nancy L Bartlett; Bruce D Cheson; Lois E Shepherd; Ranjana H Advani; Joseph M Connors; Brad S Kahl; Leo I Gordon; Sandra J Horning; Christian Steidl; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-11-26       Impact factor: 44.544

2.  A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.

Authors:  Vivek Subbiah; Robert E Brown; Mary F McGuire; Jamie Buryanek; Filip Janku; Anas Younes; David Hong
Journal:  Oncotarget       Date:  2014-01-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.